#zaynich
Wockhardt secures US FDA approval for antibiotic Zaynich
Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in …
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock e…
Wockhardt gets CDSCO nod for Zaynich antibiotic
Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potenti…